ATE491791T1 - Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionen - Google Patents

Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionen

Info

Publication number
ATE491791T1
ATE491791T1 AT04809538T AT04809538T ATE491791T1 AT E491791 T1 ATE491791 T1 AT E491791T1 AT 04809538 T AT04809538 T AT 04809538T AT 04809538 T AT04809538 T AT 04809538T AT E491791 T1 ATE491791 T1 AT E491791T1
Authority
AT
Austria
Prior art keywords
cells
oligonucleotide
virus
analog
oligonucleotide analog
Prior art date
Application number
AT04809538T
Other languages
English (en)
Inventor
Patrick Iversen
David Stein
Original Assignee
Avi Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avi Biopharma Inc filed Critical Avi Biopharma Inc
Application granted granted Critical
Publication of ATE491791T1 publication Critical patent/ATE491791T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04809538T 2003-08-05 2004-08-05 Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionen ATE491791T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49304303P 2003-08-05 2003-08-05
US51200303P 2003-10-16 2003-10-16
PCT/US2004/025335 WO2005030800A2 (en) 2003-08-05 2004-08-05 Oligonucleotide analog and method for treating flavivirus infections

Publications (1)

Publication Number Publication Date
ATE491791T1 true ATE491791T1 (de) 2011-01-15

Family

ID=34396142

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04809538T ATE491791T1 (de) 2003-08-05 2004-08-05 Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionen

Country Status (10)

Country Link
US (3) US7807801B2 (de)
EP (1) EP1654363B1 (de)
JP (4) JP2007527227A (de)
KR (2) KR100943473B1 (de)
CN (1) CN1829794B (de)
AT (1) ATE491791T1 (de)
AU (1) AU2004276226B2 (de)
CA (1) CA2533218C (de)
DE (1) DE602004030583D1 (de)
WO (1) WO2005030800A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8796235B2 (en) * 2003-02-21 2014-08-05 University Of South Florida Methods for attenuating dengue virus infection
WO2005030800A2 (en) 2003-08-05 2005-04-07 Avi Biopharma, Inc. Oligonucleotide analog and method for treating flavivirus infections
WO2005056021A1 (en) * 2003-12-04 2005-06-23 University Of South Florida Polynucleotides for reducing respiratory syncytial virus gene expression
EP2500430B1 (de) 2004-06-28 2017-03-08 The University Of Western Australia Antisense-Oligonukleotide zur Induktion von Exon-Skipping sowie Verfahren zur Verwendung davon
DK1766012T3 (da) 2004-07-02 2011-09-19 Avi Biopharma Inc Antisense-antibakteriel fremgangsmåde og forbindelse
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007030691A2 (en) 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
WO2007030576A2 (en) 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
PL2735568T3 (pl) 2006-05-10 2018-02-28 Sarepta Therapeutics, Inc. Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami
US8785407B2 (en) 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
EP2046954A2 (de) 2006-07-31 2009-04-15 Curevac GmbH Nukleinsäure der formel (i): gixngn, oder (ii): cixmcn, insbesondere als immunstimulierendes mittel/adjuvans
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
JP5721441B2 (ja) 2008-01-31 2015-05-20 キュアバック ゲーエムベーハーＣｕｒｅｖａｃ Ｇｍｂｈ 免疫賦活剤／アジュバントとしての式（Ｉ）（ＮｕＧｌＸｍＧｎＮｖ）ａで表される核酸分子及びその誘導体
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2010042547A1 (en) * 2008-10-06 2010-04-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of an rna from west nile virus
KR20250016146A (ko) 2008-10-24 2025-02-03 사렙타 쎄러퓨틱스 인코퍼레이티드 Dmd를 위한 다중 엑손 스키핑 조성물
WO2011026139A1 (en) 2009-08-31 2011-03-03 Gen-Probe Incorporated Dengue virus assay
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
KR102239374B1 (ko) 2009-11-12 2021-04-14 더 유니버시티 오브 웨스턴 오스트레일리아 안티센스 분자 및 이를 이용한 질환 치료방법
KR101944119B1 (ko) 2009-11-13 2019-01-30 사렙타 쎄러퓨틱스 인코퍼레이티드 안티센스 항바이러스 화합물 및 인플루엔자 바이러스 감염을 치료하는 방법
KR20200133284A (ko) * 2010-05-28 2020-11-26 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
WO2012014116A1 (en) * 2010-07-29 2012-02-02 Bigtec Private Limited Probes and primers for detection of dengue
ES2558106T3 (es) 2010-07-30 2016-02-02 Curevac Ag Formación de complejos de ácidos nucleicos con componentes catiónicos disulfuro-reticulados para la transfección e inmunoestimulación
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
CN107693797B (zh) 2011-05-05 2021-05-11 萨勒普塔医疗公司 肽寡核苷酸缀合物
KR102142689B1 (ko) 2011-11-18 2020-08-10 사렙타 쎄러퓨틱스, 인코퍼레이티드 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
CN105378081B (zh) 2013-03-14 2019-06-14 萨勒普塔医疗公司 用于治疗肌营养不良的外显子跳跃组合物
EP3662912B1 (de) 2013-03-15 2025-12-03 Sarepta Therapeutics, Inc. Verbesserte eteplirsen dosierungen zur behandlung von duchenne muskeldystrophie
US9695421B2 (en) 2013-07-05 2017-07-04 Bioneer Corporation Dengue virus-specific siRNA, double helix oligo-RNA structure comprising siRNA, and composition for suppressing proliferation of dengue virus comprising RNA structure
BR112016003361A2 (pt) 2013-08-21 2017-11-21 Curevac Ag vacina do vírus sincicial respiratório (rsv)
CA2936286A1 (en) 2014-04-01 2015-10-08 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
KR101805980B1 (ko) 2015-07-27 2017-12-07 안재용 수지원료의 이물질 제거장치
CN116804031A (zh) * 2016-09-20 2023-09-26 科罗拉多州立大学董事会法人团体 使用亚磷酰胺化学法合成主链修饰的吗啉代寡核苷酸和嵌合体
EP3555293A4 (de) 2016-12-15 2020-08-12 Meharry Medical College Viruzide
WO2019118458A1 (en) * 2017-12-11 2019-06-20 Respirogen, Inc. Devices and methods for delivery of oxygen to a wound
EP4277641A4 (de) * 2021-02-26 2025-03-19 Duke University Zusammensetzungen und verfahren zur verbesserung der gentherapie

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003454A1 (en) 1990-08-14 1992-03-05 Isis Pharmaceuticals, Inc. Inhibition of influenza virus type a, ann arbor strain h2n2 by antisense oligonucleotides
EP0856579A1 (de) * 1997-01-31 1998-08-05 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH Ein Verfahren zur Zubereitung von Antisense Oligonukleotiden
US20030044979A1 (en) 2001-04-05 2003-03-06 Isis Pharmaceuticals Inc. Antisense modulation of phospholipid scramblase I expression
US20030087851A1 (en) 1999-01-20 2003-05-08 Biozak, Inc. Pharmaceutical composition for treating or preventing influenza, and novel oligonucleotide
WO2000078341A1 (en) * 1999-06-21 2000-12-28 Murdoch Childrens Research Institute A method for the prophylaxis and/or treatment of medical disorders
US6936467B2 (en) * 2000-03-27 2005-08-30 University Of Delaware Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
WO2002068637A2 (en) * 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
AU2002342057B2 (en) * 2001-10-16 2009-01-22 Avi Biopharma, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
WO2005030800A2 (en) 2003-08-05 2005-04-07 Avi Biopharma, Inc. Oligonucleotide analog and method for treating flavivirus infections

Also Published As

Publication number Publication date
CN1829794B (zh) 2011-06-08
CA2533218A1 (en) 2005-04-07
KR20060056978A (ko) 2006-05-25
JP2010042015A (ja) 2010-02-25
JP2007527227A (ja) 2007-09-27
AU2004276226B2 (en) 2009-07-30
AU2004276226A1 (en) 2005-04-07
CA2533218C (en) 2014-11-18
JP2016041065A (ja) 2016-03-31
US9347063B2 (en) 2016-05-24
KR20100003302A (ko) 2010-01-07
EP1654363A2 (de) 2006-05-10
US20100292189A1 (en) 2010-11-18
KR101032853B1 (ko) 2011-05-06
WO2005030800A3 (en) 2005-06-16
US8618270B2 (en) 2013-12-31
CN1829794A (zh) 2006-09-06
KR100943473B1 (ko) 2010-02-19
EP1654363B1 (de) 2010-12-15
JP2013212110A (ja) 2013-10-17
US20050096291A1 (en) 2005-05-05
WO2005030800A2 (en) 2005-04-07
US7807801B2 (en) 2010-10-05
US20150038462A1 (en) 2015-02-05
DE602004030583D1 (de) 2011-01-27

Similar Documents

Publication Publication Date Title
ATE491791T1 (de) Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionen
DE602007006457D1 (de) Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektion
ATE552347T1 (de) Oligonukleotidverbindung und verfahren zur behandlung von nidovirusinfektionen
WO2007030576A3 (en) Antisense antiviral compound and method for treating picornavirus infection
EP1507791A4 (de) Antisense-antivirusmittel und verfahren zur behandlung einer ssrna-virusinfektion
CA2526893A1 (en) Inhibition of the expression of huntingtin gene
WO2007030691A3 (en) Antisense antiviral compound and method for treating picornavirus infection
WO2006033933A3 (en) Antisense antiviral compound and method for treating ssrna viral infection
ATE289519T1 (de) Zusammensetzungen und verfahren zur behandlung von hepatitis c virus-bedingten erkrankungen
WO2006047683A3 (en) Antisense antiviral compound and method for treating influenza viral infection
CA2520541A1 (en) Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field
Toulme et al. Targeting RNA structures by antisense oligonucleotides
ATE495253T1 (de) Die replikation des hepatitis-c-virus-replikons hemmendes nukleaseresistentes rna-aptamer
WO2005013905A3 (en) SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION
RU2008141977A (ru) КОМПОЗИЦИИ dsPHK И СПОСОБЫ ЛЕЧЕНИЯ HPV-ИНФЕКЦИИ
J. Blake et al. RNA interference for viral infections
JP4545091B2 (ja) Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸
Mohapatra et al. Evaluation of in vitro inhibitory potential of small interfering RNAs directed against various regions of foot-and-mouth disease virus genome
EA200500873A1 (ru) Набор анти-вич- олигонуклеотидов и способ их применения для профилактики и лечения синдрома приобретенного иммунодефицита
Arzumanov et al. Inhibition of the HIV-1 Tat protein-TAR RNA interaction by 2'-O-methyl oligoribonucleotides
Fu et al. Inhibition of rabies virus infection by an oligodeoxynucleotide complementary to rabies virus genomic RNA
AU2013205445B2 (en) Antisense antiviral compound and method for treating picornavirus infection
IL158739A0 (en) Anti-virus agent
DK1537210T3 (da) Decoy-oligonukleotid-inhibering af CD40-ekspression
DE50015171D1 (de) Rna polymerase i transkriptionsfaktor tif-ia

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties